GOLD REPORT 2023
FOLLOW-UP TREATMENT
82% of patients with COPD eligible for maintenance therapy experience breathlessness
14**
Only 2 out of 8 COPD patients are exacerbators15††
Only 2 out of 8 COPD patients are exacerbators15††
ICS use in COPD requires careful balance16
GOLD 2023 RECOMMENDATIONS
Escalation to LAMA/LABA in patients with persistent breathlessness on bronchodilator monotherapy
1
If a patient on LAMA/LABA continues to exacerbate, consider adding ICS if eosinophils are ≥100 cells/μL1
No addition of ICS for persistent breathlessness, unless accompanied by exacerbations1
In a real-world analysis of over 140,000 patients with COPD, LAMA/LABA/ICS did not offer benefit vs. LAMA/LABA in terms of all-cause mortality or exacerbations17‡‡
PC-CRP-104007 - November 2022 